{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:36:56Z","timestamp":1790350616103,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Natural Science Foundation of China-Youth Science Fund","award":["No. 82204453"],"award-info":[{"award-number":["No. 82204453"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01563-2","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:26:05Z","timestamp":1752139565000},"page":"770-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical presentation of PD-1\/PD-L1 immune checkpoint inhibitors induced cystitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Jian","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q et al (2022) The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 13:964442","journal-title":"Front Immunol"},{"key":"1563_CR2","doi-asserted-by":"publisher","first-page":"955163","DOI":"10.3389\/fonc.2022.955163","volume":"12","author":"C Cheng","year":"2022","unstructured":"Cheng C et al (2022) Overcoming resistance to PD-1\/PD-L1 inhibitors in esophageal cancer. Front Oncol 12:955163","journal-title":"Front Oncol"},{"issue":"1","key":"1563_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","volume":"25","author":"Y Cho","year":"2025","unstructured":"Cho Y, Ahn S, Kim KM (2025) PD-L1 as a biomarker in gastric cancer immunotherapy. J Gastric Cancer 25(1):177\u2013191","journal-title":"J Gastric Cancer"},{"issue":"1","key":"1563_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL (2022) Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther 7(1):331","journal-title":"Signal Transduct Target Ther"},{"key":"1563_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"PF Wang","year":"2017","unstructured":"Wang PF et al (2017) Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8:730","journal-title":"Front Pharmacol"},{"key":"1563_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01554-3","author":"J Xiao","year":"2025","unstructured":"Xiao J et al (2025) Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis. Invest New Drugs. https:\/\/doi.org\/10.1007\/s10637-025-01554-3","journal-title":"Invest New Drugs"},{"issue":"1","key":"1563_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ucl.2022.09.006","volume":"50","author":"JM Masterson","year":"2023","unstructured":"Masterson JM, Casta\u00f1eda PR, Kim J (2023) Pathophysiology and clinical biomarkers in interstitial cystitis. Urol Clin North Am 50(1):39\u201352","journal-title":"Urol Clin North Am"},{"issue":"1","key":"1563_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JU.0000000000002756","volume":"208","author":"JQ Clemens","year":"2022","unstructured":"Clemens JQ et al (2022) Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome. J Urol 208(1):34\u201342","journal-title":"J Urol"},{"issue":"9","key":"1563_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CJI.0000000000000484","volume":"46","author":"Y Fan","year":"2023","unstructured":"Fan Y et al (2023) Recurrent cystitis associated with 2 programmed death 1 inhibitors: a rare case report and literature review. J Immunother 46(9):341\u2013345","journal-title":"J Immunother"},{"issue":"6","key":"1563_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/iju5.12532","volume":"5","author":"H Fukunaga","year":"2022","unstructured":"Fukunaga H et al (2022) A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab. IJU Case Rep 5(6):521\u2013523","journal-title":"IJU Case Rep"},{"issue":"18","key":"1563_CR11","doi-asserted-by":"publisher","first-page":"18491","DOI":"10.1002\/cam4.6449","volume":"12","author":"X Ge","year":"2023","unstructured":"Ge X et al (2023) Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: a monocentric real-world observational study. Cancer Med 12(18):18491\u201318502","journal-title":"Cancer Med"},{"issue":"2","key":"1563_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pop.2019.01.001","volume":"46","author":"KB Kolman","year":"2019","unstructured":"Kolman KB (2019) Cystitis and pyelonephritis: diagnosis, treatment, and prevention. Prim Care 46(2):191\u2013202","journal-title":"Prim Care"},{"issue":"5","key":"1563_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/14740338.2024.2431587","volume":"24","author":"F Zheng","year":"2025","unstructured":"Zheng F et al (2025) Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024. Expert Opin Drug Saf 24(5):557\u2013564","journal-title":"Expert Opin Drug Saf"},{"key":"1563_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1146\/annurev-immunol-101220-032117","volume":"40","author":"GS Bowyer","year":"2022","unstructured":"Bowyer GS et al (2022) Tissue immunity in the bladder. Annu Rev Immunol 40:499\u2013523","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1563_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11934-024-01236-2","volume":"26","author":"J Aqeel","year":"2024","unstructured":"Aqeel J et al (2024) Management strategies for patients with non-infectious cystitis: a review of the literature. Curr Urol Rep 26(1):6","journal-title":"Curr Urol Rep"},{"issue":"4","key":"1563_CR16","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/ijms23042194","volume":"23","author":"SD Chung","year":"2022","unstructured":"Chung SD et al (2022) Specific impacts of ketamine on bladder dysfunction and associated histological alterations in rats-a time course validation through transmission electron microscopy. Int J Mol Sci 23(4):2194","journal-title":"Int J Mol Sci"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"757069","DOI":"10.3389\/fonc.2021.757069","volume":"11","author":"L Tu","year":"2021","unstructured":"Tu L et al (2021) Case Report: a case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events. Front Oncol 11:757069","journal-title":"Front Oncol"},{"key":"1563_CR18","unstructured":"Lala V, Leslie SW, Minter DA (2025) Acute cystitis. In: StatPearls. StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC, Treasure Island"},{"issue":"3","key":"1563_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.annemergmed.2018.06.012","volume":"73","author":"SY Liang","year":"2019","unstructured":"Liang SY, Camins BC (2019) Urine culture and uncomplicated cystitis: a bigger picture? Ann Emerg Med 73(3):308\u2013309","journal-title":"Ann Emerg Med"},{"issue":"1","key":"1563_CR20","doi-asserted-by":"publisher","first-page":"015017","DOI":"10.1088\/2057-1976\/ad0f3e","volume":"10","author":"S Abbaspour","year":"2023","unstructured":"Abbaspour S et al (2023) Multimodality radiomics prediction of radiotherapy-induced the early proctitis and cystitis in rectal cancer patients: a machine learning study. Biomed Phys Eng Express 10(1):015017","journal-title":"Biomed Phys Eng Express"},{"issue":"4","key":"1563_CR21","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/RLU.0000000000005091","volume":"49","author":"L Guo","year":"2024","unstructured":"Guo L, Deng S, Shen G (2024) Eosinophilic cystitis mimicking malignancy on FDG PET\/CT. Clin Nucl Med 49(4):e191\u2013e192","journal-title":"Clin Nucl Med"},{"issue":"10","key":"1563_CR22","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.3748\/wjg.v21.i10.3139","volume":"21","author":"SG Han","year":"2015","unstructured":"Han SG et al (2015) Eosinophilic gastroenteritis associated with eosinophilic cystitis: computed tomography and magnetic resonance imaging findings. World J Gastroenterol 21(10):3139\u20133145","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1563_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JU.0000000000001334","volume":"205","author":"JF Jhang","year":"2021","unstructured":"Jhang JF et al (2021) Clinical relevance of bladder histopathological findings and their impact on treatment outcomes among patients with interstitial cystitis\/bladder pain syndrome: an investigation of the european society for the study of interstitial cystitis histopathological classification. J Urol 205(1):226\u2013235","journal-title":"J Urol"},{"issue":"12","key":"1563_CR24","first-page":"859","volume":"96","author":"S Chaieb","year":"2018","unstructured":"Chaieb S et al (2018) Interstitial cystitis: elements of diagnosis and place of histopathological examination. About 16 cases. Tunis Med 96(12):859\u2013864","journal-title":"Tunis Med"},{"issue":"Suppl 1","key":"1563_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/iju.12370","volume":"21","author":"Y Logadottir","year":"2014","unstructured":"Logadottir Y et al (2014) Inflammation characteristics in bladder pain syndrome ESSIC type 3C\/classic interstitial cystitis. Int J Urol 21(Suppl 1):75\u201378","journal-title":"Int J Urol"},{"issue":"3","key":"1563_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/JU.0000000000002278","volume":"207","author":"Y Akiyama","year":"2022","unstructured":"Akiyama Y et al (2022) Overexpression of HIF1\u03b1 in Hunner lesions of interstitial cystitis: pathophysiological implications. J Urol 207(3):635\u2013646","journal-title":"J Urol"},{"key":"1563_CR27","doi-asserted-by":"publisher","first-page":"1423123","DOI":"10.3389\/fimmu.2024.1423123","volume":"15","author":"C Di","year":"2024","unstructured":"Di C, Yu T, Ni L (2024) Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report. Front Immunol 15:1423123","journal-title":"Front Immunol"},{"issue":"5","key":"1563_CR28","first-page":"e25486","volume":"14","author":"A Obayashi","year":"2022","unstructured":"Obayashi A et al (2022) Non-bacterial cystitis with increased expression of programmed cell death ligand 1 in the urothelium: an unusual immune-related adverse event after atezolizumab administration for metastatic breast cancer. Cureus 14(5):e25486","journal-title":"Cureus"},{"issue":"6","key":"1563_CR29","first-page":"638","volume":"4","author":"M Cervigni","year":"2015","unstructured":"Cervigni M (2015) Interstitial cystitis\/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol 4(6):638\u2013642","journal-title":"Transl Androl Urol"},{"key":"1563_CR30","doi-asserted-by":"crossref","unstructured":"Lin HY et al (2021) Urinary Biomarkers in Interstitial Cystitis\/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome. Diagnostics (Basel) 12(1):75","DOI":"10.3390\/diagnostics12010075"},{"key":"1563_CR31","doi-asserted-by":"publisher","first-page":"1562852","DOI":"10.3389\/fphar.2025.1562852","volume":"16","author":"Z Mao","year":"2025","unstructured":"Mao Z et al (2025) Hydrogen sulfide and ferroptosis inhibition underlies the dietary restriction-induced protection against cyclophosphamide cystitis. Front Pharmacol 16:1562852","journal-title":"Front Pharmacol"},{"key":"1563_CR32","doi-asserted-by":"publisher","first-page":"115047","DOI":"10.1016\/j.bcp.2022.115047","volume":"200","author":"J Zhao","year":"2022","unstructured":"Zhao J et al (2022) Activation of CXCL13\/CXCR5 axis aggravates experimental autoimmune cystitis and interstitial cystitis\/bladder pain syndrome. Biochem Pharmacol 200:115047","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1563_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.62347\/BLED2401","volume":"12","author":"BM Zwaans","year":"2024","unstructured":"Zwaans BM et al (2024) Evaluating symptom severity and urinary cytokine levels in interstitial cystitis\/bladder pain syndrome patients, with and without Hunner\u2019s lesions. Am J Clin Exp Urol 12(2):110\u2013118","journal-title":"Am J Clin Exp Urol"},{"issue":"2","key":"1563_CR34","first-page":"86","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70(2):86\u2013104","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1563_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) Toxicity management working group. J Immunother Cancer 5(1):95","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1563_CR36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","volume":"6","author":"A Young","year":"2018","unstructured":"Young A, Quandt Z, Bluestone JA (2018) The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res 6(12):1445\u20131452","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1563_CR37","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/nau.23459","volume":"37","author":"Y Chen","year":"2018","unstructured":"Chen Y et al (2018) Expression of programmed death ligand-1 on bladder tissues is detected in a clinically and histologically well-defined interstitial cystitis cohort. Neurourol Urodyn 37(4):1396\u20131404","journal-title":"Neurourol Urodyn"},{"key":"1563_CR38","doi-asserted-by":"publisher","first-page":"1051577","DOI":"10.3389\/fimmu.2022.1051577","volume":"13","author":"J Li","year":"2022","unstructured":"Li J et al (2022) Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: case report and literature review. Front Immunol 13:1051577","journal-title":"Front Immunol"},{"key":"1563_CR39","doi-asserted-by":"publisher","first-page":"1226993","DOI":"10.3389\/fimmu.2023.1226993","volume":"14","author":"Q Zhou","year":"2023","unstructured":"Zhou Q et al (2023) Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis\/cystitis and review of the literature. Front Immunol 14:1226993","journal-title":"Front Immunol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01563-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01563-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01563-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:31Z","timestamp":1760195011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01563-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01563-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}